Target ability and therapy efficacy of immunoliposomes using a humanized antihepatoma disulfide-stabilized Fv fragment on tumor cells

Journal of Pharmaceutical Sciences

Volumn 95, Issue 1, 2006, Pages 192-199

  Hu, Haiyang ^a   Chen, Dawei ^a   Liu, Yanfang ^b   Deng, Yihui ^a   Yang, Shoujing ^b   Qiao, Mingxi ^a   Zhao, Jun ^b   Zhao, Xiuli ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cytotoxicity; Humanized antihepatoma disulfide stabilized Fv (hdsFv25); Immunoliposome; Immunoreactivity; Immunotherapy; Peptides in bee venom (PBV)

Indexed keywords

BEE VENOM; CARBOXYLIC ACID; CHOLESTEROL; IMMUNOLIPOSOME; MACROGOL; PEPTIDE DERIVATIVE; PHOSPHATIDYLCHOLINE; SUCCINIMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; DISULFIDE; IMMUNOGLOBULIN FRAGMENT; LIPOSOME;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL KILLING; CONTROLLED STUDY; DISULFIDE BOND; ENGINEERING; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOLYSIS; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; MOUSE; NONHUMAN; SOYBEAN; STEREOSPECIFICITY; TUMOR CELL; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; DRUG SCREENING; HELA CELL; IMMUNOLOGY; LIVER CELL CARCINOMA; NUDE MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; BEE VENOMS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISULFIDES; HELA CELLS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645215307     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20517     Document Type: Article

References (30)

1. Kang JH, Shin SY, Jang SY, Lee MK, Hahm KS. 1998. Release of aqueous contents from phospholipid vesicles induced by cecropin A (1-8)-magainin 2 (1-12) hybrid and its analogues. J Pept Res 52:45-50.
2. Ling CQ, Li B, Zhang C, Gu W, Li SX, Huang XQ, Zhang YN. 2004. Anti-hepatocarcinoma effect of recombinant adenovirus carrying melittin gene. Zhonghua Gan Zang Bing Za Zhi 12:741-744. [Article in Chinese]
3. Leuschner C, Enright FM, Gawronska B, Hansel W. 2003. Membrane disrupting lytic peptide conjugates destroy hormone dependent and indepen-dent breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 78:17-27.
4. Shin SY, Kang JH, Hahm KS. 1999. Structure-antibacterial, antitumor and hemolytic activity relationships of cecropin A-magainin 2 and cecropin A-melittin hybrid peptides. J Pept Res 53:82-90.
5. Xing Liu, Dawei Chen, Liping Xie, Rongqing Zhang. 2002. Effect of honey bee venom on proliferation of K1735M2 mouse melanoma cell in-vitro and growth of murine B16 melanomas invivo. JPP 54:1-8.
6. Forssen E, Willis M. 1998. Ligand-targeted liposomes. Adv Drug Deliv Rev 29:249-271.
7. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby MR, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Paphadjopoulos D, Benz CC. 2002. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172-1181.
8. Maruy K, Holmberg E, Kennel SJ. 1990. Characterization of in vivo immunoliposome targeting to pulmonary endothelium. J Pharm Sci 79:978-984.
9. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. 2001. Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95-113.
10. Poon R, Fox YF, Connor TH, editors. 1997. In: Biotechnology international: international developments in the biotechnology industry. San Francisco: Universal Medical Press, pp 113-128.
11. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan SH, Whitlow M. 1988. Single-chain antigen-binding proteins. Science (Wash. DC) 242:423-426.
12. Worn A, Pluckthun A. 2001. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305:989-1010.
13. Laukkanen ML, Alfthan K, Keinanen K. 1994. Functional immunoliposomes harboring a biosynthetically lipid-tagged single-chain antibody. Biochemistry 33:11664-11670.
14. Ulrik BN, Dmitri BK, Edward MP, Hong Keelung, et al. 2002. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 1591:109-118.
15. Tina V, Peter H, Thomas M, Rolf M, Roland EK. 2004. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 1663:158-166.
16. De Kruif J, Storm G, van Bloois L, Logtenberg T. 1996. Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Lett 399:232-236.
17. Paolo F. 1981. Succinic Half-esters of poly (ethylene glycol)s and their benzotriazole and imidazole derivatives as oligomeric drug-binding matrices. Macromol Chem 182:2183-2219.
18. Maruyama Kazuo, Takizawa Tomoko. 1995. Targeting of novel immunoliposomes modified with amphipathic poly (ethylene glycol) s conjugated at their distal terminals to monoclonal antibody. Biochim Biophys Acta 1234:74-80.
19. Peterson GL. 1977. A simplication of the protein assay method of Lowry et al, which is more generally applicable. Anal Biochem 83:346-356.
20. Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ, Bankert RB. 1993. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 53:964-3967.
21. Enoch HG, Strittmatter P. 1979. Formation and properties of 1000-A-diameter, single-bilayer phosholipid vesicles. Proc Natl Acad Sci USA 76:145-149.
22. Yoshioka H. 1991. Surface modification of hemoglobin-containingliposomes with polyethylene glycol prevents liposomeaggregation in blood-plasma. Biomaterials 12:861-864.
23. Vertut-Doi A, Ishiwata H, Miyajima K. 1996. Binding and uptake of liposomes containing a poly (ethylene glycol) derivative of cholesterol (stealth liposomes) by the macrophage cell line J774: influence of PEG content and its molecular weight. Biochim Biophys Acta 278:19-28.
24. Harrington KJ, Lewanski CR, Stewart JSW. 2000a. Liposomes as vehicles for targeted therapy of cancer. Part1: preclinical development. Clin Oncol 12:2-15.
25. Harrington KJ, Lewanski CR, Stewart JSW. 2000b. Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development. Clin Oncol 12:16-24.
26. Theresa MA, Ester B, Christian BH, Samuel Z. 1995. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1237:99-108.
27. Gerben AK, Henriette WM, Morselt, Maria JV. 1999. Selective transfer of a lipophilic prodrug of 5-fluorodeoxywridine from immunoliposomes to colon cancer cells. Biochim Biophys Acta 1420:153-167.
28. Ulla KN, Peter AS, Wim HD, Wendy Van Overveld OWM, Conny ME, Boekhors T. 1995. Design of immunoliposomes directed against human ovarian carcinoma. Biochim Biophys Acta 1235:126-139.
29. Sybille R, Bian Jiang, John RS, Michel L. 2002. The presence of PEG-lipids in liposomes does not reduce melittin binding but decreases melittin-induced leakage. Biochim Biophys Acta 1558:211-221.
30. Toni B, Michel L. 1995. Study of vesicle leakage induced by melittin. Biochim Biophys Acta 1235:452-460.